Stonepine Capital Management’s Radiopharm Theranostics RADX Stock Holding History

Stonepine Capital Management’s Portfolio RADX Stock Details RADX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$739K	Hold	51,000,000	–	–	0.3%	46
2025 Q4	$851K	Buy	+51,000,000	New	+$272M	0.62%	41

Other funds holding RADX

SCM

Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return

HSBC Holdings London, United Kingdom $192B AUM 27.2% 1-Year Est. Return

Regal Partners Sydney, NSW, Australia $1.84B AUM 54.78% 1-Year Est. Return

PNC Financial Services Group Pittsburgh, Pennsylvania $173B AUM 20.72% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return

Stonepine Capital Management's RADX Position: Q1 2026 in Review

Stonepine Capital Management held its Radiopharm Theranostics (RADX) position steady in Q1 2026 at 51,000,000 shares worth $739K. The position accounts for 0.3% of the portfolio, ranked #46.

Stonepine Capital Management first reported a position in RADX in Q4 2025 and has held it in 2 quarters since. The position peaked at $851K in Q4 2025. 7 funds tracked by Wall St. Rank hold RADX as of Q1 2026.

Stonepine Capital Management held 51,000,000 shares of Radiopharm Theranostics worth $739K as of Q1 2026.
Stonepine Capital Management left its Radiopharm Theranostics share count unchanged in Q1 2026.
Radiopharm Theranostics made up 0.3% of Stonepine Capital Management's portfolio in Q1 2026, its #46 holding.
Stonepine Capital Management first reported a position in Radiopharm Theranostics in Q4 2025 and has held it in 2 quarters since.
Stonepine Capital Management's Radiopharm Theranostics position peaked at $851K in Q4 2025.
7 funds tracked by Wall St. Rank held Radiopharm Theranostics as of Q1 2026.

Based on Stonepine Capital Management's 13F filing for Q1 2026, filed 14 May 2026.